Concepedia

F. Baas

FB

4

Publications

304

Citations

4

H-Index

2005

Active since

Affiliations

University of Freiburg(Current)

Bayer (Germany)

Boehringer Ingelheim (Germany)

F. Baas is an author at University of Freiburg specializing in pharmacotherapy, medicine, and pharmacology.

Top concepts

Publications per year

2005–2009

4

Publications

4

Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors

K. Mross, Martin Štefanič, Daniela Gmehling et al. · Clinical Cancer Research · 2009 · 164 citations

Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib

K. Mross, Simone Steinbild, F. Baas et al. · European Journal of Cancer · 2006 · 99 citations

, , +5

A clinical phase I, pharmacokinetic (PK), and pharmacodynamic study of twice daily BIBF 1120 in advanced cancer patients

K. Mross, Daniela Gmehling, Annette Frost et al. · Journal of Clinical Oncology · 2005 · 26 citations

, , +16

Phase I study of BAY 43–9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors

Simone Steinbild, F. Baas, Daniela Gmehling et al. · Journal of Clinical Oncology · 2005 · 15 citations

, , +13

Rows per page

1–4 of 4